Kabra Drugs Limited is an Indian public limited company listed on the **Bombay Stock Exchange (BSE)**. Historically a pharmaceutical entity, the company is currently undergoing a radical strategic transformation. Under new leadership, it is transitioning from a legacy pharma business into a multi-sector conglomerate with interests spanning **Defence, Aerospace, Electric Vehicles (EV), and Advanced Healthcare**. This pivot is supported by a massive capital restructuring and a relocation of its corporate base to **Chennai, Tamil Nadu**. --- ### **Strategic Pivot: From Pharmaceuticals to "Aanjaay Industries"** The company is rebranding itself as **Aanjaay Industries Limited** to reflect a broadened operational scope. This transformation involves moving the **Registered Office** from **Indore, Madhya Pradesh**, to **Chennai**, aligning the company with its majority directors and providing access to a superior talent pool and industrial infrastructure. The Board has approved a comprehensive amendment to the **Main Objects** of the Memorandum of Association (MOA) to enter high-growth, technology-driven sectors: * **Defence & Aerospace:** A landmark joint venture with **PT. Bhinneka Dwi Persada (Indonesia)** to manufacture **UAVs (Rajawali 330)**, **Cargo Drones**, **Hovercrafts**, and **Mobile Command and Control Vehicles (MCCV)**. * **Electric Vehicles (EV):** Manufacturing and distribution of **EV components** and full vehicle systems through the acquisition of **Vassmaan Automotive Pvt Ltd**. * **Advanced Healthcare:** Expansion into **E-Pharmacy**, **Medical Imaging**, **Gene Mapping**, and **Medical Tourism**. * **Industrial & Agro:** Diversification into **Steel/Tin Sheets**, **Solar Energy** equipment, **Dairy products**, and **Agro-farming**. --- ### **Core Pharmaceutical & Manufacturing Operations** Despite the diversification, the company maintains its roots in the pharmaceutical sector, shifting from passive trading to an active distribution and manufacturing model. * **Proprietary Brand Distribution:** The company has shifted to a pan-India distribution model for its own medicinal brands. It has signed an agreement with **M/s. MR FRANCHISE** to appoint **200 channel partners** (state-wise and district-wise) across India. * **Manufacturing Infrastructure:** The company has received **FDA permission** for its **Chennai facility**. Furthermore, it is pursuing the acquisition of **AMR Pharma India Pvt Ltd**, a **WHO GMP** certified company, to enter the high-margin **Critical Care and Oncology** segments. * **Permaculture Manufacturing:** Integration of permaculture-based processes into its pharmaceutical manufacturing vertical. --- ### **Capital Structure and Aggressive Fundraising** To fund its multi-sector ambitions, the company has significantly scaled its capital base through successive preferential allotments to non-promoter investors. | Date | Action | Details | | :--- | :--- | :--- | | **Jan 2024** | **Auth. Capital Increase** | Raised from **₹5 Crore** to **₹20 Crore** | | **July 2024** | **Preferential Allotment** | **56,90,500 shares** at **₹10** (At Par) | | **Feb 2025** | **Preferential Allotment** | **1,36,28,750 shares** at **₹16** (Incl. **₹6** Premium) | | **Dec 2024** | **Auth. Capital Increase** | Raised from **₹20 Crore** to **₹40 Crore** | | **Jan 2026 (Prop)** | **Proposed Fundraise** | **2,64,14,300 shares** to raise **₹42.26 Crore** | As of the latest reporting, the **Paid-up Capital** stands at **Rs. 23,70,78,500** (comprising 2,37,07,850 equity shares of **Rs. 10** each). --- ### **Financial Performance and Historical Context** The company’s historical financials reflect a period of operational dormancy and restructuring. | Particulars (INR) | F.Y. 2022-23 | F.Y. 2021-22 | | :--- | :--- | :--- | | **Revenue from Operations** | **Nil** | **Nil** | | **Other Income** | **63,764** | **Nil** | | **Total Expenses** | **34,42,767** | **18,53,943** | | **Profit After Tax (Loss)** | **(33,79,003)** | **(18,53,943)** | | **Earnings Per Share (EPS)** | **(0.77)** | **(0.42)** | **Key Financial Observations:** * **Dividends:** No dividends have been recommended due to **accumulated losses**. * **Solvency:** Management maintains that the company can meet all liabilities falling due within **one year**, with financial liabilities consisting primarily of **short-term borrowings**. * **Asset Management:** Title deeds for immovable properties are held directly in the company’s name; however, no revaluation of assets was conducted in the most recent fiscal year. --- ### **Governance, Leadership, and Professional Services** The company is "broad-basing" its board to include technical and financial experts to oversee its new business verticals. * **Key Appointments:** **Mr. N. Aravind** (Managing Director, 5-year term) and **Mr. T. Pavanasam** (CFO). **Mr. B.V. Anatha Kumar** (Whole-Time Director) has notably agreed to serve **without remuneration** to preserve cash flow. * **Internal Audit:** **M/s K E K and Associates LLP** has been appointed for F.Y. 2024-25. This firm provides a wide range of services including **Statutory Audits**, **International Taxation**, and **Wealth Management**. * **Statutory Audit:** **M/s PPN and Company** was appointed in September 2024 for a **5-year tenure** following the resignation of the previous auditor. --- ### **Risk Profile and Regulatory Challenges** Investors should note significant regulatory and operational risks associated with the company’s transition phase. * **Exchange Surveillance:** The company is currently under **GSM: Stage 4** (Graded Surveillance Measure) on the BSE, which imposes **restricted trading** conditions. * **LODR Non-Compliance:** As of March 31, 2025, the company was certified as **non-compliant** with **SEBI (LODR) Regulations 17 to 27** regarding Corporate Governance. * **Operational Inactivity:** The company has recently recorded **zero sales**, meaning it currently has minimal exposure to **Credit Risk** or **Currency Risk**, but faces high **Strategic Risk** regarding the execution of its new business plans. * **Internal Controls:** Historical gaps include a failure to maintain proper **fixed asset records** and delays in appointing an **Internal Auditor** as per Section 138 of the Companies Act. ### **Risk Management Framework** The Board utilizes a structured categorization to monitor threats: * **Strategic Risk:** Annual reviews of the diversification roadmap. * **Liquidity Risk:** Treasury monitoring of **forecasted vs. actual cash flows**. * **Regulatory Risk:** Ongoing efforts to update **Statutory Registrars** and resolve exchange-related compliance issues.